2014
Posttreatment Effects of Topiramate Treatment for Heavy Drinking
Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcohol Clinical And Experimental Research 2014, 38: 3017-3023. PMID: 25581656, PMCID: PMC4293099, DOI: 10.1111/acer.12578.Peer-Reviewed Original ResearchConceptsPercent days abstinentHeavy drinking daysTopiramate treatmentHeavy drinkingDrinking daysHeavy drinkersAllele homozygotesPlacebo-controlled trialEffects of topiramateEnd of treatmentPersistent therapeutic effectKainate receptor subunitsHigher percent days abstinentTherapeutic effectTreatment goalsAlcohol-related problemsAllele carriersDays abstinentAbstinent daysPosttreatment effectsReceptor subunitsReduced drinkingSingle nucleotide polymorphismsStatistical significanceComplete dataTopiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. American Journal Of Psychiatry 2014, 171: 445-452. PMID: 24525690, PMCID: PMC3997125, DOI: 10.1176/appi.ajp.2013.13081014.Peer-Reviewed Original ResearchConceptsHeavy drinking daysHeavy drinkersTopiramate treatmentDaily doseHeavy drinkingTopiramate's effectsDrinking daysAbstinent daysUse of topiramateMaximal daily doseWeeks of treatmentC allele homozygotesPersonalized treatment optionsEnzyme γ-glutamyl transpeptidasePlacebo groupΓ-glutamyl transpeptidaseTreatment optionsTreatment completionPharmacogenetic findingsTreatment goalsAlcohol-related problemsKainate receptorsTreatment groupsBrief counselingAlcohol dependence
2008
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Mäkelä R, Kranzler HR. Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. Alcohol Clinical And Experimental Research 2008, 32: 1159-1166. PMID: 18537939, PMCID: PMC2950972, DOI: 10.1111/j.1530-0277.2008.00735.x.Peer-Reviewed Original ResearchConceptsOpioid receptor geneSingle nucleotide polymorphismsTherapeutic effectReceptor geneHeavy drinkingOpioid antagonist nalmefenePlacebo-controlled trialKappa-opioid receptorsNaltrexone treatment responseHeavy drinking daysReceptor gene polymorphismsOpioid receptor gene polymorphismsAsn40Asp polymorphismNalmefene treatmentPolymorphic variationAntagonist treatmentMedication responseTreatment responsePharmacogenetic analysisReceptor gene variationDrinking daysNalmefeneGene polymorphismsHeavy drinkersConflicting results